Interactive effects of the BDNF Val66Met polymorphism and posttraumatic stress disorder on cognition in U.S. military veterans.


Journal

Psychoneuroendocrinology
ISSN: 1873-3360
Titre abrégé: Psychoneuroendocrinology
Pays: England
ID NLM: 7612148

Informations de publication

Date de publication:
08 2022
Historique:
received: 20 02 2022
revised: 16 05 2022
accepted: 30 05 2022
pubmed: 10 6 2022
medline: 18 6 2022
entrez: 9 6 2022
Statut: ppublish

Résumé

Posttraumatic stress disorder (PTSD) is associated with mild-to-moderate deficits in cognition. The Met allele of the brain-derived neurotrophic factor (BDNF) Val66Met gene may also be associated with deficits in cognition. However, findings are inconsistent and may be sensitive to moderating variables such as psychopathology. While emerging research suggests that PTSD and the Met allele may interact, few studies have replicated this effect or examined the interactive effect of PTSD and the Met allele on subjective cognition. To address this gap, the current study analyzed data from European-American (EA) U.S. military veterans (n = 1244) who participated in the National Health and Resilience in Veterans Study (NHRVS) to examine the main and interactive effects of BDNF Val66Met genotype and probable PTSD on objective and subjective cognition. Results revealed significant (p's < 0.001) interactions between Met allele carrier status and probable PTSD in objective and subjective cognition. Among individuals with probable PTSD (n = 131), the Met allele was associated with poorer objective (p < .001, d = 0.62) and subjective cognition (p = .001, d = 0.53). Among individuals without PTSD (n = 1113), the Met allele was not significantly associated with objective or subjective cognition. These findings suggest that PTSD may moderate the association between Met allele carrier status and cognition. Implications of these results for the mitigation of cognitive dysfunction in older veterans are discussed.

Identifiants

pubmed: 35679772
pii: S0306-4530(22)00161-5
doi: 10.1016/j.psyneuen.2022.105820
pii:
doi:

Substances chimiques

Brain-Derived Neurotrophic Factor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105820

Subventions

Organisme : NIMH NIH HHS
ID : K23 MH111977
Pays : United States

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Auteurs

Colton S Rippey (CS)

Department of Psychology, University of Kentucky, United States. Electronic address: colton.rippey@uky.edu.

Robert H Pietrzak (RH)

Clinical Neurosciences Division, US Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, VA Connecticut Healthcare System, United States; Department of Psychiatry, Yale School of Medicine, United States.

Paul Maruff (P)

Mental Health Research Institute, University of Melbourne, Australia; Cogstate Ltd., Melbourne, Victoria, Australia.

Thomas G Adams (TG)

Department of Psychology, University of Kentucky, United States; Department of Psychiatry, Yale School of Medicine, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH